Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EM1H | ISIN: US03770N1019 | Ticker-Symbol:
NASDAQ
28.03.25
20:37 Uhr
39,240 US-Dollar
-0,010
-0,03 %
1-Jahres-Chart
APOGEE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APOGEE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APOGEE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln
12.03.Apogee Therapeutics (NASDAQ:APGE) Earns "Outperform" Rating from Wedbush5
11.03.Apogee Therapeutics, Inc. - 8-K, Current Report-
10.03.TD Cowen reiterates buy on Apogee Therapeutics stock2
05.03.Apogee Therapeutics: Steigende Verluste trotz wachsender Marktchancen3
03.03.Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial1
03.03.Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy4
03.03.Apogee Therapeutics reports FY results3
03.03.Apogee Therapeutics, Inc. - 8-K, Current Report-
03.03.Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results109Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)...
► Artikel lesen
03.03.Apogee Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)51Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head...
► Artikel lesen
03.03.Apogee Therapeutics, Inc. - 10-K, Annual Report-
20.02.Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month Low - Here's What Happened2
03.02.Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis121Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb....
► Artikel lesen
03.02.Apogee Therapeutics, Inc. - 8-K, Current Report-
30.01.Here's Why Apogee Therapeutics, Inc. (APGE) Will Double in 20252
11.01.CEO von Apogee Therapeutics verkauft Aktien im Wert von 732.692 US-Dollar2
16.12.24Apogee Therapeutics-Direktor Mark McKenna erwirbt Aktien im Wert von 990.775 US-Dollar2
10.12.24Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions140Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus...
► Artikel lesen
10.12.24Apogee Therapeutics, Inc. - 8-K, Current Report-
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1